- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04246047
Avaliação da Eficácia e Segurança de Belantamab Mafodotin, Bortezomib e Dexametasona Versus Daratumumab, Bortezomib e Dexametasona em Participantes com Mieloma Múltiplo Recidivante/Refratário (DREAMM 7)
DREAMM 7: Um estudo multicêntrico, aberto e randomizado de fase III para avaliar a eficácia e a segurança da combinação de belantamab mafodotin, bortezomib e dexametasona (B-Vd) em comparação com a combinação de daratumumab, bortezomib e dexametasona (D-Vd) ) em participantes com mieloma múltiplo recidivante/refratário
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Acesso expandido
Contactos e Locais
Locais de estudo
-
-
-
Cologne, Alemanha, 50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Alemanha, 89081
- GSK Investigational Site
-
-
Bavaria
-
München, Bavaria, Alemanha, 81377
- GSK Investigational Site
-
Würzburg, Bavaria, Alemanha, 97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Alemanha, 40225
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Alemanha, 07747
- GSK Investigational Site
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Austrália, 2050
- GSK Investigational Site
-
Liverpool, New South Wales, Austrália, 2170
- GSK Investigational Site
-
Newcastle, New South Wales, Austrália, 2298
- GSK Investigational Site
-
St Leonards, New South Wales, Austrália, 2065
- GSK Investigational Site
-
Wollongong, New South Wales, Austrália, 2500
- GSK Investigational Site
-
-
Queensland
-
Benowa, Queensland, Austrália, 4217
- GSK Investigational Site
-
Herston, Queensland, Austrália, 4029
- GSK Investigational Site
-
-
South Australia
-
Ashford, South Australia, Austrália, 5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill, Victoria, Austrália, 3128
- GSK Investigational Site
-
Heidelberg, Victoria, Austrália, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Austrália, 3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch, Western Australia, Austrália, 6150
- GSK Investigational Site
-
Nedlands, Western Australia, Austrália, 6009
- GSK Investigational Site
-
-
-
-
-
Joinville, Brasil, 89201-260
- GSK Investigational Site
-
Natal, Brasil, 59075-740
- GSK Investigational Site
-
Rio de Janeiro, Brasil, 22775001
- GSK Investigational Site
-
São Paulo, Brasil, 04537-080
- GSK Investigational Site
-
São Paulo, Brasil, 05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasil, 88020-210
- GSK Investigational Site
-
-
-
-
-
Roeselare, Bélgica, 8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette, Brussels Capital, Bélgica, 1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert, Brussels Capital, Bélgica, 1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Bélgica, 9000
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London, Ontario, Canadá, N6A 5W9
- GSK Investigational Site
-
Toronto, Ontario, Canadá, M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Beijing, China, 100191
- GSK Investigational Site
-
Beijing, China, 100020
- GSK Investigational Site
-
Changchun, China, 130012
- GSK Investigational Site
-
Guangzhou, China, 510060
- GSK Investigational Site
-
Guangzhou, China, 510515
- GSK Investigational Site
-
Hangzhou, China, 310003
- GSK Investigational Site
-
Jinan, China, 250012
- GSK Investigational Site
-
Nanjing, China, 210008
- GSK Investigational Site
-
Shenyang, China, 110001
- GSK Investigational Site
-
Suzhou, China, 215006
- GSK Investigational Site
-
Tianjin, China, 300020
- GSK Investigational Site
-
Zhengzhou, China, 450052
- GSK Investigational Site
-
-
-
-
-
Pusan, Coréia do Sul, 49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, Coréia do Sul, 13620
- GSK Investigational Site
-
Seoul, Coréia do Sul, 06351
- GSK Investigational Site
-
Seoul, Coréia do Sul, 06591
- GSK Investigational Site
-
Ulsan, Coréia do Sul, 44033
- GSK Investigational Site
-
-
-
-
-
Barcelona, Espanha, 08035
- GSK Investigational Site
-
Barcelona, Espanha, 08916
- GSK Investigational Site
-
Cáceres, Espanha, 10003
- GSK Investigational Site
-
Gijón, Espanha, 33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega, Espanha, 08908
- GSK Investigational Site
-
MOstoles Madrid, Espanha, 28933
- GSK Investigational Site
-
Madrid, Espanha, 28007
- GSK Investigational Site
-
Madrid, Espanha, 31008
- GSK Investigational Site
-
Murcia, Espanha, 30008
- GSK Investigational Site
-
PamplonaNavarra, Espanha, 31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Espanha, 28223
- GSK Investigational Site
-
Salamanca, Espanha, 37007
- GSK Investigational Site
-
-
-
-
Arizona
-
Yuma, Arizona, Estados Unidos, 85364
- GSK Investigational Site
-
-
Kansas
-
Mission, Kansas, Estados Unidos, 66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver, North Carolina, Estados Unidos, 80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash, Ohio, Estados Unidos, 45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler, Texas, Estados Unidos, 75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke, Virginia, Estados Unidos, 24014
- GSK Investigational Site
-
-
-
-
-
Amiens, França, 80054
- GSK Investigational Site
-
Caen, França, 14033
- GSK Investigational Site
-
Nice, França, 06200
- GSK Investigational Site
-
Paris, França, 75651
- GSK Investigational Site
-
Rennes, França, 35033
- GSK Investigational Site
-
-
-
-
-
Athens, Grécia, 11528
- GSK Investigational Site
-
Thessaloniki, Grécia, 54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli, East Macedonia and Thrace, Grécia, 681 00
- GSK Investigational Site
-
-
-
-
-
Groningen, Holanda, 9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht, South Holland, Holanda, 3318 AT
- GSK Investigational Site
-
-
-
-
-
Jerusalem, Israel, 91120
- GSK Investigational Site
-
Kfar Saba, Israel, 44281
- GSK Investigational Site
-
Ramat Gan, Israel, 52621
- GSK Investigational Site
-
Tel Aviv, Israel, 64239
- GSK Investigational Site
-
-
-
-
-
Bergamo, Itália, 24127
- GSK Investigational Site
-
Bologna, Itália, 40138
- GSK Investigational Site
-
Brescia, Itália, 25123
- GSK Investigational Site
-
Catania, Itália, 95123
- GSK Investigational Site
-
Meldola FC, Itália, 47014
- GSK Investigational Site
-
Milan, Itália, 20133
- GSK Investigational Site
-
Ravenna, Itália, 48121
- GSK Investigational Site
-
Roma, Itália, 00168
- GSK Investigational Site
-
Siena, Itália, 53100
- GSK Investigational Site
-
Torino, Itália, 10126
- GSK Investigational Site
-
-
-
-
-
Aichi, Japão, 467-8602
- GSK Investigational Site
-
Aichi, Japão, 441-8570
- GSK Investigational Site
-
Aomori, Japão, 030-8553
- GSK Investigational Site
-
Ehime, Japão, 790-8524
- GSK Investigational Site
-
Fukuoka, Japão, 806-8501
- GSK Investigational Site
-
Fukuoka, Japão, 807-8555
- GSK Investigational Site
-
Fukuoka, Japão, 810-8563
- GSK Investigational Site
-
Fukuoka, Japão, 815-8555
- GSK Investigational Site
-
Gifu, Japão, 503-8502
- GSK Investigational Site
-
Gunma, Japão, 377-0280
- GSK Investigational Site
-
Hyōgo, Japão, 670-8540
- GSK Investigational Site
-
Kanagawa, Japão, 247-8533
- GSK Investigational Site
-
Kanagawa, Japão, 221-0855
- GSK Investigational Site
-
Kochi, Japão, 781-8555
- GSK Investigational Site
-
Nagano, Japão, 392-8510
- GSK Investigational Site
-
Okayama, Japão, 701-1192
- GSK Investigational Site
-
Osaka, Japão, 545-8586
- GSK Investigational Site
-
Osaka, Japão, 530-0012
- GSK Investigational Site
-
Shizuoka, Japão, 411-8777
- GSK Investigational Site
-
-
-
-
-
Christchurch, Nova Zelândia, 8011
- GSK Investigational Site
-
Dunedin, Nova Zelândia, 9054
- GSK Investigational Site
-
Takapuna Auckland, Nova Zelândia, 1309
- GSK Investigational Site
-
Wellington, Nova Zelândia, 6021
- GSK Investigational Site
-
-
-
-
-
Chorzów, Polônia, 41-500
- GSK Investigational Site
-
Krakow, Polônia, 30510
- GSK Investigational Site
-
Lodz, Polônia, 93-513
- GSK Investigational Site
-
Lublin, Polônia, 20-081
- GSK Investigational Site
-
Lublin, Polônia, 20-090
- GSK Investigational Site
-
Nowy Sącz, Polônia, 33-300
- GSK Investigational Site
-
Poznan, Polônia, 60-569
- GSK Investigational Site
-
Warsaw, Polônia, 02-781
- GSK Investigational Site
-
-
-
-
-
Bournemouth, Reino Unido, BH7 7DW
- GSK Investigational Site
-
Cardiff, Reino Unido, CF14 4XW
- GSK Investigational Site
-
Dundee, Reino Unido, DD1 9SY
- GSK Investigational Site
-
Leicester, Reino Unido, LE1 5WW
- GSK Investigational Site
-
London, Reino Unido, W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent, Reino Unido, ST4 6QG
- GSK Investigational Site
-
Sutton, Reino Unido, SM2 5PT
- GSK Investigational Site
-
-
-
-
-
Moscow, Rússia, 125284
- GSK Investigational Site
-
Nizhny Novgorod, Rússia, 603126
- GSK Investigational Site
-
Novosibirsk, Rússia, 630087
- GSK Investigational Site
-
Saint Petersburg, Rússia, 191024
- GSK Investigational Site
-
Saint Petersburg, Rússia, 197 089
- GSK Investigational Site
-
Samara, Rússia, 443021
- GSK Investigational Site
-
Saratov, Rússia, 410028
- GSK Investigational Site
-
Ufa, Rússia, 450083
- GSK Investigational Site
-
-
-
-
-
Brno, Tcheca, 625 00
- GSK Investigational Site
-
Hradec Králové, Tcheca, 500 05
- GSK Investigational Site
-
Ostrava, Tcheca, 708 52
- GSK Investigational Site
-
Prague, Tcheca, 128 08
- GSK Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Belantamab mafodotin e Bortezomib mais Dexametasona (Braço A)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
Comparador Ativo: Daratumumabe e Bortezomibe mais Dexametasona (Braço B)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free Survival (PFS)
Prazo: Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Número de participantes com achados oculares anormais no exame oftalmológico
Prazo: Até 73 meses
|
Até 73 meses
|
|
|
Complete Response Rate (CRR)
Prazo: Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
Prazo: Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
Prazo: Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
Prazo: Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
Prazo: Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
Prazo: Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
Prazo: Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Prazo: Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
Prazo: Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
Prazo: Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
Prazo: Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Prazo: Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
Prazo: Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Prazo: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Prazo: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Prazo: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Prazo: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
Prazo: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Prazo: Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Prazo: Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
Prazo: Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: GSK Clinical Trials, GlaxoSmithKline
Publicações e links úteis
Publicações Gerais
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Neoplasias de Células Plasmáticas
- Distúrbios hemostáticos
- Paraproteinemias
- Distúrbios das Proteínas Sanguíneas
- Distúrbios hemorrágicos
- Doenças hemic e linfáticas
- Mieloma múltiplo
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos policíclicos
- Produtos químicos inorgânicos
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Esteróides, fluorados
- Pregadienetriols
- Ácidos borônicos
- Ácidos, não carboxílico
- Ácidos
- Compostos de boro
- Pirazinas
- Bortezomibe
- Dexametasona
- daratumumab
- Mafodotina de Belantamab
Outros números de identificação do estudo
- 207503
- 2018 (Concessão/Contrato do NIH dos EUA)
- 2018-003993-29 (Identificador de registro: EudraCT (EU))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .